



Pregnancy Outcomes in a Group of Egyptian Patients with Systemic Lupus Erythematosus: A Cohort Study

Thesis

Submitted for Partial Fulfillment of

M.D Degree in Internal Medicine

Presented by

Ayah Taha Moussa Ali Abdel-Zaher

M.B.B.Ch, M.Sc. (Internal medicine)

Ain Shams University

Under Supervision of

Prof. Dr. Dalia Fayez Mohammed

Professor of Internal Medicine, Rheumatology and Immunology

Faculty of Medicine – Ain Shams University

Prof. Dr. Howaida ElSayed Mansour

Professor of Internal Medicine, Rheumatology and Immunology

Faculty of Medicine – Ain Shams University

Prof. Dr. Alaa El-Din Hamed El-Feky

Professor of Obstetric and Gynecology

Faculty of Medicine – Ain Shams University

Prof. Sherin Mohamed Hosny

Professor of Internal Medicine, Rheumatology and Immunology

Faculty of Medicine – Ain Shams University

Dr. Caroline Samy Morad

Assistant Professor of Internal Medicine, Rheumatology and Immunology

Faculty of Medicine – Ain Shams University

Faculty of Medicine - Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبِحَانَكَ لَا مَعْلَمَ لَنَا
إِلَّا مَا مَعْلَمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I feel always indebted to Allah the Most Beneficent and Merciful.

I wish to express my deepest thanks, gratitude and appreciation to Prof. Dr. Dalia Fayez Mohammed, Professor of Internal Medicine, Rheumatology and Immunology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to Prof. Dr. Howaida ElSayed Mansour, Professor of Internal Medicine, Rheumatology and Immunology, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.

I am deeply thankful to Prof. Dr. Alaa El-Din Hamed ElFeky, Professor of Obstetric and Gynecology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.

Really I can hardly find the words to express my gratitude to Dr. Sherin Mohamed Hosny, Assistant Professor of Internal Medicine, Rheumatology and Immunology, Faculty of Medicine, Ain Shams University, for her supervision, continuous help, encouragement throughout this.

I wish to express my deepest thanks, gratitude and appreciation to Dr. Caroline Samy Morad, Lecturer of Internal Medicine, Rheumatology and Immunology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Ayah Taha Moussa Ali Abdel-Zaher

List of Contents

Title	Page No.
List of Tables.....	5
List of Figures.....	9
List of Abbreviations.....	13
Introduction.....	- 1 -
Aim of the Work.....	19
Review of Literature	
▪ Systemic Lupus Erythematosus.....	20
▪ SLE and Pregnancy.....	69
Subjects and Methods.....	102
Results.....	114
Discussion.....	167
Summary.....	185
Conclusion.....	190
Recommendations.....	191
References.....	192
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	ISN/RPS 2003 classification of lupus nephritis.	28
Table 2:	Pleuropulmonary manifestations of Systemic Lupus Erythematosus.....	32
Table 3:	Neuropsychiatric syndromes seen in systemic lupus erythematosus.....	33
Table 4:	Autoantibodies of systemic lupus erythematosus.....	38
Table 5:	ACR/SLICC Revised Criteria for Diagnosis of Systemic Lupus Erythematosus.....	41
Table 6:	EULAR/ACR proposed new classification criteria for SLE.....	43
Table 7:	SLE disease activity index (SLEDAI).	45
Table 8:	Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index.	48
Table 9:	Blood chemistry changes during normal pregnancy.	70
Table 10:	Some Laboratory changes during normal pregnancy	70
Table 11:	Classification criteria for definite APS.....	75
Table 12:	Contraindications to pregnancy in lupus patient.....	79
Table 13:	Differentiating features between preeclampsia and lupus flare	82
Table 14:	Drugs commonly used in lupus patients and their effect on pregnancy and breast feeding.....	99
Table 15:	SLEPDAI Score	104
Table 16:	Descriptive data and Comparative study between pregnant SLE group and pregnant control group regarding demographic data and medical comorbidities at the first visit.....	114

List of Tables (cont...)

Table No.	Title	Page No.
Table 17:	Comparison between pregnant SLE patients and controls as regards to obstetric history.....	116
Table 18:	Descriptive data of SLE group regarding disease manifestations before pregnancy.....	119
Table 19:	Descriptive data of serological investigations of SLE group at the first visit.....	121
Table 20:	Comparison between SLEPDAI scores at first visit and at each trimester in SLE group.....	122
Table 21:	Comparison between SLE patients with and without APS/aPL regarding SLEPDAI score during pregnancy.	124
Table 22:	Descriptive data regarding the status of disease activity assessed by SLEPDAI score at first visit and the frequency of different system flares among the SLE patients' group during pregnancy.	125
Table 23:	Comparison between SLE patients with and without APS/aPL regarding SLE manifestations.....	127
Table 24:	Descriptive data of drug intake among SLE group before and during pregnancy.	128
Table 25:	Comparison between the SLE patients and controls regarding routine laboratory data of the first trimester.....	130
Table 26:	Comparison between the SLE patients and controls regarding routine laboratory data of the second trimester.....	132
Table 27:	Comparison between the SLE patients and controls regarding routine laboratory data of the third trimester	136

List of Tables (cont...)

Table No.	Title	Page No.
Table 28:	Comparison between the three trimesters in the SLE group regarding the routine and serological laboratory data.....	140
Table 29:	Comparison between the three trimesters in the control group regarding the routine laboratory data.....	141
Table 30:	Comparison between SLE patients with and without APS/sPL regarding some routine labs of each trimester.....	142
Table 31:	Comparison between SLE patients and controls regarding medical comorbidities during the current pregnancy.....	143
Table 32:	Comparison between SLE patients with and without APS/sPL regarding medical comorbidities during the pregnancy.....	144
Table 33:	Comparison between SLE patients and controls regarding mode of delivery and frequency of obstetric complications.....	145
Table 34:	Comparison between SLE patients with and without APS/aPL regarding frequency of obstetric complications.....	148
Table 35:	Comparison between SLE patients and controls regarding fetal outcome and frequency of fetal complications.	149
Table 36:	Comparison between SLE patients with and without APS/aPL regarding fetal outcome and frequency of fetal complications.	151
Table 37:	Comparison between SLE patients with and without pre-eclampsia.....	152
Table 38:	Comparison between the SLE patients regarding the presence and absence of acute kidney injury (AKI).	155

List of Tables (cont...)

Table No.	Title	Page No.
Table 39:	Comparison between SLE patients with and without premature neonates.	157
Table 40:	Comparison between SLE patients with and without fetal loss.	159
Table 41:	Univariate logistic regression analysis for predictors of preeclampsia	161
Table 42:	Multivariate logistic regression analysis for predictors of preeclampsia.	161
Table 43:	Univariate logistic regression analysis for predictors of AKI	162
Table 44:	Multivariate regression analysis for predictors of AKI.....	163
Table 45:	Univariate logistic analysis for predictors of prematurity	164
Table 46:	Multivariate regression analysis for predictors of prematurity.	165
Table 47:	Univariate logistic regression analysis for predictors of fetal loss.	166

List of Figures

Fig. No.	Title	Page No.
Fig. 1:	Arthritis of left wrist, metacarpophalangeal and proximal interphalangeal joints in a patient with SLE.....	22
Fig. 2:	Discoid lupus with definitive atrophic dermal scarring in an afro-Caribbean	25
Fig. 3:	A proposed algorithm for the handling of glucocorticoid (GC) therapy in SLE	53
Fig. 4:	Pathogenesis of SLE and treatment targets that have been or being evaluated	58
Fig. 5:	Recommendations for induction of improvement in Patients with ISN Class III/IV LN	64
Fig. 6:	Treatment of non-renal SLE—recommended drugs with respective grading of recommendation.....	65
Fig. 7:	Recommendations for induction of improvement in Patients with ISN Class III/IV LN	65
Fig. 8:	Pragmatic approach for SLE treatment	66
Fig. 9:	Preeclampsia as a cardiorenal syndrome of pregnancy	74
Fig. 10:	Comparison between SLE group and control group regarding BMI at the first visit.	115
Fig. 11:	Comparison between SLE group and control group regarding the frequency of DM and HTN at first visit.	115
Fig. 12:	Comparison between SLE group and control group regarding median gravidity.	117
Fig. 13:	Comparison between SLE group and control group regarding median number of parity.	117
Fig. 14:	Comparison between SLE group and control group regarding the median of the number of previous abortions.....	118

List of Figures (cont...)

Fig. No.	Title	Page No.
Fig. 15:	Comparison between SLE group and control group regarding the frequency of previous preterm labor.	118
Fig. 16:	Descriptive data of SLE group regarding disease manifestations before pregnancy.	120
Fig. 17:	SLEPDAI scores at first visit and for each trimester of pregnancy categorized.	123
Fig. 18:	The frequency of SLE flares during pregnancy.	126
Fig. 19:	Descriptive data of SLE drug treatment during pregnancy.	129
Fig. 20:	Frequency of patterns of Azathioprine use during pregnancy.	129
Fig. 21:	Comparison between the two groups as regards to frequency of active urinary sediments at the first trimester.	131
Fig. 22:	Comparison between the two groups as regards to 24- hour urinary protein at the first trimester.	131
Fig. 23:	Comparison between the two groups as regards to mean serum ESR level at the second trimester.	133
Fig. 24:	Comparison between the two groups as regards to mean serum hemoglobin at the second trimester.	134
Fig. 25:	Comparison between the two groups as regards to mean platelets count at the second trimester.	134
Fig. 26:	Comparison between the two groups as regards to frequency of active urinary sediments at the second trimester.	135

List of Figures (cont...)

Fig. No.	Title	Page No.
Fig. 27:	Comparison between the two groups as regards to total 24-hour urinary protein at the second trimester.	135
Fig. 28:	Comparison between the two groups as regards to median ESR at the third trimester.....	137
Fig. 29:	Comparison between the two groups as regards mean platelets count at the third trimester.....	137
Fig. 30:	Comparison between the two groups as regards to mean hemoglobin at the third trimester.....	138
Fig. 31:	Comparison between the two groups as regards to active urinary sediments at the third trimester.	138
Fig. 32:	Comparison between the two groups as regards to 24-hour urinary protein at the third trimester.	139
Fig. 33:	Comparison between the two groups regarding medical and obstetric complications during pregnancy.	147
Fig. 34:	Comparison between the two groups regarding mode of delivery.	147
Fig. 35:	Comparison between the two groups regarding the frequency of fetal complications.....	150
Fig. 36:	Comparison between the two groups regarding fetal weight.	150
Fig. 37:	Comparison between SLE patients with the presence and absence of pre-eclampsia (PE) presence of aPL and HTN.....	153

List of Figures (cont...)

Fig. No.	Title	Page No.
Fig. 38:	Comparison between SLE patients with the presence and absence of pre-eclampsia (PE) total 24-hour urinary protein.	153
Fig. 39:	Comparison between SLE patients with and without pre-eclampsia (PE) regarding remission duration.....	154
Fig. 40:	Comparison between SLE patients with and without AKI regarding remission duration showing shorter remission duration in SLE patients without AKI.....	156
Fig. 41:	Comparison between SLE patients with and without prematurity regarding remission duration showing that shorter remission duration is associated with higher risk of prematurity.....	158
Fig. 42:	Factors associated with significantly higher prematurity among SLE group.	158
Fig. 43:	Comparison between SLE patients with and without fetal loss regarding remission duration showing short duration of remission is associated with fetal loss in SLE patients.....	160
Fig. 44:	Comparison between SLE patients with the presence and absence of fetal loss.....	160

List of Abbreviations

Abb.	Full term
AAO	American Academy of Ophthalmology
ABW	Actual Body Weight
ACEI	Angiotensin-converting enzyme Inhibitor
ACL	Anticardiolipin antibody
ACLE	Acute Cutaneous Lupus Erythematosus
AFI.....	Amniotic fluid index
ALP.....	Alkaline phosphatase
ALT	Alanine Transferase
ANA	Antinuclear antibody
ANCA	Anti Neutrophil Cytoplasmic Antibody
Anti-DNA	Anti Deoxyribonucleic acid
Anti-Sm	Anti-Smith antibody
aPL	Antiphospholipid antibodies
APS	Antiphospholipid Syndrome
AST	Aspartate Transferase
AZA.....	Azathioprine
B.....	Regression coefficient
BILAG	British Isles Lupus Assessment Group
BILAG2004- P	British Isles Lupus Assessment Group 2004 for pregnancy
Blys.....	B-lymphocyte stimulator
BUN.....	Blood urea nitrogen
C3.....	Complement 3
C4.....	Complement 4
CCLE	Chronic Cutaneous Lupus Erythematosus
CHB	Congenital Heart Block
CI	Confidence interval
CK.....	Creatinine kinase
CS	Corticosteroids
CSA	Cyclosporin
CYC	Cyclophosphamide
DM.....	Diabetes Mellitus
ECLAM	European Consensus Lupus Activity Measure

List of Abbreviations (cont...)

Abb.	Full term
ESR	Erythrocyte sedimentation ratio
FACIT.....	Functional Assessment Chronic Illness Therapy
FDA	Federal Drug Association
FSS	Fatigue Severity Scale
Hb	Hemoglobin
HCQ.....	Hydroxychloroquine
HELLP	Hemolysis, elevated liver enzymes, and low platelets
HS.....	Highly significant
HTN.....	Hypertension
IBW.....	Ideal Body Weight
IUDs	Intrauterine devices
IUFD	Intrauterine fetal death
IUGR	Fetal growth restriction
IVF	In vitro fertilization
LAC	Lupus anticoagulant
LAI-P	Lupus activity index in pregnancy
LBW	Low birth weight
LDA	Low Dose Aspirin
LMWH	Low molecular weight heparin
LN	Lupus Nephritis
MMF	Mycophenolate mofetil
m-SLAM	Modified Lupus Activity Measurement
MTX	Methotrexate
NICU	Neonatal intensive care unit
NL	Neonatal lupus
NPSLE	Neuropsychiatric Systemic Lupus Erythematosus
NS.....	Non-significant
NSAID	Non-steroidal anti-inflammatory drugs
NSLE.....	Neonatal Systemic lupus erythematosus
OR.....	Odds ratio

List of Abbreviations (cont...)

Abb.	Full term
PATCH	Preventive Approach to Congenital Heart Block with Hydroxychloroquine trial
PLT	Platelets
PROMISSE	Study (Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic Lupus Erythematosus)
P-value.....	Probability value
RCTs	Randomised Controlled Trials
S.....	Significant
S.E.	Standard error of regression coefficient
SGA	Small for Gestational Age
SCLE	Subacute Cutaneous Lupus Erythematosus
SELENA.....	Safety of Estrogens in Lupus Erythematosus National Assessment
SLAM.....	Systemic Lupus Activity Measure
SLE	Systemic Lupus Erythematosus
SLEDAI.....	Systemic Lupus Erythematosus Disease Activity Index
SLEPDAI	Systemic Lupus Erythematosus in Pregnancy Activity Index
SLICC	Systemic Lupus International Collaborating Clinics
TAC	Tacrolimus
UFH	Unfractionated Heparin
US.....	Utrasound
Wald	Statistical test
WBC	White blood cell
Wks.....	Weeks